A research team at the Center for Neuroscience Imaging Research (CNIR) within the Institute for Basic Science (IBS), together ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

Three recently published studies by Medical University of South Carolina researchers each adopted a unique approach to ...

Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety ...

Multi-agency response team provides updates on One Health approach to New World screwworm; biosecurity and sterile fly ...

On 9 December 2025, Relation Therapeutics announced a multi-program collaboration with Novartis, securing US$55 million in ...

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific ...

Chonnam National University has once again solidified its international reputation as Korea's leading institution in "nano-regenerative medicine" ...

The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade. The trial results set the ...

Daniel Ives You can reverse the age of cells all the way down to zero in just a few weeks. So you can actually take a ...